DESTINY-Breast06研究新突破,拓展抗HER2治疗获益人群。 美国临床肿瘤学会(ASCO)年会于2024年5月31日至6月4日在美国芝加哥盛大召开,本次大会公布了多项乳腺癌领域的最新成果,其中德曲妥珠单抗(T-DXd)作为HER2靶向的代表性ADC药物更是讨论的热...
[5] Xu W, Jiang Y, Xu L, et al. HER2-low status may predict poor neoadjuvant chemotherapy response in HR-negative breast cancer: a real-world multicenter study. Jpn J Clin Oncol. 2023 Jun 1;53(6):463-471. 审...
该项试验中,每个治疗组的患者之前接受过内分泌治疗种类的中位数为2种。在整个试验人群中,14.9%的德曲妥珠单抗治疗组患者(n=65)和19.2%的化疗组患者(n=82)曾接受过一种内分泌治疗。试验中没有患者在转移之后接受过化疗治疗。中位随访时间为 18.2 个月。截至2024年3月18日数据截止时,共有119名患者(14%)仍在...
Beyond the status quo: finding tech that works for you The Challenge HR has long been tasked with building engaging, high-performing workplaces while relying on tools that fall short of their needs. From cobbling together “free” solutions to squeezing functionality from HRIS systems, many org...
status lenovo return policy technical support pc support data center support smart devices support motorola mobile support forums all technical support customer support help placing an order warranty extensions order replacement parts shopping help order support existing order help check order status lenovo ...
2024 Fortune® World’s Most Admired Companies™* 18 consecutive years Everest Group Leader Multi-Process Human Resources Outsourcing 13 consecutive years Leader Payroll Services 10 years Leader Multi-Country Payroll (MCP) Solutions 10 years
“Alien” Changed To “Noncitizen”USCIS no longer refers to individuals as “aliens,” instead referring to them as “noncitizens.” Additionally, Section 1 under Status 4, USCIS clarified that a noncitizen employee must provide a USCIS number, Form I-4 Admission number, or Foreign Passport ...
星期一 13:32:31 48.0905 -122.6602 ↘150° 82 151 229 FlightAware ADS-B 星期一 13:32:47 48.0850 -122.6555 ↘149° 86 159 221 -14 FlightAware ADS-B (KNOW) 星期一 13:33:03 48.0799 -122.6510 ↘151° 87 161 221 14 FlightAware ADS-B (KORS) 星期一 13:33:19 48.0738 -122.6457 ↘...
The efficacy of neoadjuvant therapy varies significantly with hormone receptor (HR) status for patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer (BC). Despite extensive research on HER2 + BC, the optimal neoadjuva
The evaluation of MMR and HRR status is essential in the clinical decision-making process to tailor both the diagnostic and therapeutic approach in the sporadic setting of MMRd and HRD tumors. Unsurprisingly, the inactivation of MMR genes in the germline leads to an increased susceptibility and ea...